The Editor in Chief retracted this article (1) because of significant concerns regarding a number of Figures presented in this work, which question the integrity of the data. Figure 2C and 6B - some plots appear to have been re-use between the two figures. Additionally, there is a close similarity between a scatter plot in these two figures and one published in an earlier article by unrelated authors (2) Figure 8B (sh-XIST) and C (shRNA) -these images appear to have been published previously in an unrelated publication (3) The authors were unable to provide raw data and stated that the figures were obtained through a commercial lab hired to perform some of the experiments for this study. Author Guanzhen Li agrees to this retraction. Author Shuli Wang has not responded to any correspondence from the editor or publisher about this retraction. The online version of this article contains the full text of the retracted article as electronic supplementary material.

References

1) Wang, S., Li, G. LncRNA XIST inhibits ovarian cancer cell growth and metastasis via regulating miR-150-5p/PDCD4 signaling pathway. Naunyn-Schmiedeberg's Arch Pharmacol (2020). https://doi.org/10.1007/s00210-020-01808-2 2) Wang, Q. et al. Physcion 8-O-β-glucopyranoside inhibits clear-cell renal cell carcinoma bydownregulating hexokinase II and inhibiting glycolysis. Biomedicine & Pharmacotherapy (2018) https://doi.org/10.1016/j.biopha.2018.05.013 3) Liu, B., Yu, S. Amentoflavone suppresses hepatocellular carcinoma by repressing hexokinase 2 expression through inhibiting JAK2/STAT3 signaling. Biomedicine & Pharmacotherapy (2018) https://doi.org/10.1016/j.biopha.2018.07.177